Zhu et al. detected IDH mutations in 20% of the patients (15.5% IDH1 and 4.5% IDH2) in their study of 200 patients with resected intrahepatic CC (6); no significant differences in DFS or OS were reported among patients with different IDH mutation statuses. This evidence concerns the gene IDH2 and cholangiocarcinoma.